VANGUARD Consortium’s Commitment to World Health Day 2024
The VANGUARD consortium is proud to join the World Health Organization in commemorating World Health Day 2024 on April 7. This year’s theme, ‘My Health, My Right,’ champions the fundamental
THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
9 partners from 5 countries
€ 6.8 million
01.01.2020 – 31.12.2024
The VANGUARD consortium is proud to join the World Health Organization in commemorating World Health Day 2024 on April 7. This year’s theme, ‘My Health, My Right,’ champions the fundamental
The VANGUARD project is currently in its 52nd month of research and has made progress in all its work packages. Specifically, the research outcomes have resulted in a significant number
On January 27-28, the VANGUARD general assembly took place in Innsbruck, Austria. Nineteen participants representing the consortium’s nine project partners gathered for a two-day program consisting of project updates, planning
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874700